ArticleBreast (Edinburgh, Scotland)2026

Real-world use of neratinib as extended adjuvant therapy in HER2-positive early-stage breast cancer: a multicentre study in mainland China and Hong Kong.

Nilupai Abudureheiyimu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.